December 20, 2017 / 1:14 PM / a month ago

BRIEF-Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose

Dec 20 (Reuters) - Opiant Pharmaceuticals Inc:

* OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

* OPIANT PHARMACEUTICALS -EXPECTS ,BEGINNING Q1 2018, CO WILL RECEIVE 90% ROYALTY, MILESTONE PAYMENTS RELATED TO NARCAN SALES DIRECTLY FROM ADAPT PHARMA​

* OPIANT PHARMACEUTICALS - ROYALTY & MILESTONE PAYMENTS DUE TO SWK HOLDINGS WILL NOW BE REDUCED TO 10% Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below